Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Neurogene Inc. faces a significant business risk with its NGN-101 program for CLN5 Batten disease, as it struggles to align with the FDA on a streamlined registrational pathway. Despite halting advancements in the gene therapy program, the company is exploring alternatives such as partnering or out-licensing, though the success of these efforts is uncertain. Additionally, Neurogene Inc. is set to incur ongoing costs from post-dosing patient observations in its Phase 1/2 clinical trial, even without a clear path to commercialization. This situation highlights potential financial and strategic challenges that could impact the company’s future prospects.
Overall, Wall Street has a Strong Buy consensus rating on NGNE stock based on 7 Buys.
To learn more about Neurogene Inc.’s risk factors, click here.
